This Multispecialty Hospital Chain Stock Rises 264% Since Listing: Profit Nearly Tripled
- September 11, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Medanta (Global Health) CMP approx Rs 1,460 (10 Sep 2026). Return since Nov 2022 listing 264.16%, rank 29 of 101. 52W range Rs 955 to Rs 1,544. Market cap approx Rs 39,300 Cr.
Quick Answer
Global Health Ltd, the company behind Medanta hospitals, is the multispecialty hospital chain stock that returned approximately 264% since its November 2022 listing. Net profit nearly tripled from FY22 to FY26 as newer hospitals in Lucknow and Patna matured. The one-year return is a more modest 11.44%, although the stock gained about 49.6% in the last six months.
This multispecialty hospital chain stock has turned Rs 1 lakh invested at its listing price into roughly Rs 3.64 lakh in under four years. Since its market debut in November 2022, the share has returned 264.16% as of 10 September 2026, ranking 29th in a screen of 101 large-cap and mid-cap NSE shares on a five-year basis, even though it has been listed for less than four.
The company is Global Health Ltd (NSE: MEDANTA), the Gurugram-based operator of the Medanta hospitals founded by cardiac surgeon Dr Naresh Trehan. The Medanta share price closed at approximately Rs 1,460 on 10 September 2026, giving the company a market value of around Rs 39,300 crore. This multispecialty hospital chain stock opened at Rs 401 on listing day against an IPO price of Rs 336, and the rise since then has come from profits nearly tripling, new hospitals in Lucknow, Patna and Noida filling up, and steady buying by domestic funds.
Click Here – Get Free Investment Predictions
How Much Has This Multispecialty Hospital Chain Stock Returned Since Listing?
The answer depends on the window. Over the full period since listing, this multispecialty hospital chain stock is a clear winner, and the last six months have been especially strong. The one-year and one-month numbers are far more modest.
| Period | Return | Rank (out of 101) |
|---|---|---|
| 1 Month | 1.38% | 80 |
| 6 Months | 49.60% | 29 |
| 1 Year | 11.44% | 69 |
| 3 Years | 103.95% | 42 |
| Since Listing (Nov 2022) | 264.16% | 29 |
The table shows an uneven path for the multispecialty hospital chain stock. It roughly doubled over three years, then spent much of the past year moving sideways before a sharp rally from its 52-week low of about Rs 955. That is why the six-month return of 49.6% sits so far above the one-year return of 11.44%.
The Medanta share price now trades between that low and a 52-week high of about Rs 1,544, around 5% below the peak. There has been no stock split or bonus issue since listing, so the 264.16% figure reflects genuine price appreciation from the Rs 401 listing-day open.
Why Did This Multispecialty Hospital Chain Stock Rise 264% Since Listing?
The short answer is earnings growth. Revenue from operations roughly doubled from approximately Rs 2,167 crore in FY22 to Rs 4,410 crore in FY26, while net profit rose from around Rs 196 crore to Rs 554 crore. For a multispecialty hospital chain stock, profit growth close to three times in four years usually leads to a re-rating, and that is what the market delivered.
Newer Hospitals Became the Growth Engine for the Multispecialty Hospital Chain Stock
The early leg of the rally came from hospitals that were young at the time of listing. Lucknow and Patna moved from start-up losses toward steady profits as occupancy improved, which lifted group margins from about 21% in FY22 to around 25% in FY24.
That developing cluster is still the fastest-growing part of the business behind this multispecialty hospital chain stock. In Q1 FY27, its total income rose approximately 54.8% year on year to Rs 498 crore, while the mature cluster of Gurugram, Indore and Ranchi grew about 10.1% with an EBITDA margin of roughly 24.1%.
Noida Ramped Up Faster Than Feared
The newest hospital in Noida started operations in November 2025 and weighed on the multispecialty hospital chain stock at first, as net profit fell to about Rs 95 crore in the December 2025 quarter as start-up costs hit the books, which is part of why the one-year return is muted.
For the multispecialty hospital chain stock, the losses are narrowing quickly. Noida’s income rose to approximately Rs 85.5 crore in Q1 FY27 from Rs 52.5 crore in the previous quarter, and its EBITDA loss shrank to about Rs 4.9 crore from Rs 23.6 crore. With 433 of a planned 550-plus beds running, the market has started to price in a profitable Noida sooner than expected.
Strong Q4 FY26 Results Sparked the Six-Month Rally
The recent move in this multispecialty hospital chain stock began with the March 2026 quarter. Revenue rose to approximately Rs 1,159 crore from Rs 931 crore a year earlier, and net profit jumped about 40% to Rs 142 crore.
For the full year FY26, total income grew around 19.6% to Rs 4,509 crore, and the board recommended a dividend of Rs 0.50 per share. Operational bed capacity climbed about 20.5% to 3,665 beds, giving investors confidence that the growth runway was intact. Steady income growth is what first drew investors to the multispecialty hospital chain stock.
Domestic Funds Kept Buying
Domestic institutions have been steady buyers of this multispecialty hospital chain stock. In 2026, a large domestic mutual fund bought 10 lakh shares from a co-founder in two separate deals, the latest at Rs 1,300 per share in June, when the multispecialty hospital chain stock had already climbed nearly 30% in three months.
Brokerages Turned More Positive
Sentiment among analysts toward the multispecialty hospital chain stock also improved. A foreign brokerage upgraded the shares to buy from hold in February 2026 and raised its target to Rs 1,500 from Rs 1,440 in May, while a domestic brokerage upgraded it to add from reduce in February. Those calls came close to the bottom of the six-month move.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Q1 FY27 Results: Revenue Growth Strong, Profit Flat
The latest quarter shows both sides of this multispecialty hospital chain stock. Revenue from operations rose approximately 26.5% year on year to Rs 1,304 crore, and total income crossed Rs 1,326 crore. Net profit, however, slipped to about Rs 157 crore from Rs 159 crore.
| Quarter | Revenue (Rs Cr) | Operating Profit (Rs Cr) | OPM | Net Profit (Rs Cr) |
|---|---|---|---|---|
| Jun 2025 (Q1 FY26) | 1,031 | 247 | 24% | 159 |
| Sep 2025 (Q2 FY26) | 1,099 | 231 | 21% | 158 |
| Dec 2025 (Q3 FY26) | 1,121 | 217 | 19% | 95 |
| Mar 2026 (Q4 FY26) | 1,159 | 244 | 21% | 142 |
| Jun 2026 (Q1 FY27) | 1,304 | 287 | 22% | 157 |
The gap between sales growth and profit growth at this multispecialty hospital chain stock comes from expansion. Higher depreciation and finance costs linked to new hospitals absorbed most of the operating gains, and the Noida losses have not fully disappeared yet.
Operating data for the multispecialty hospital chain stock looked healthy. In-patient volumes rose about 27.7%, out-patient volumes jumped around 34.5%, and average revenue per occupied bed increased approximately 5.5% to Rs 70,244. Overall occupancy was near 63%, or about 66% excluding Noida, and the average length of stay fell to 2.87 days.
Valuation and Institutional Holding
The rally has made this multispecialty hospital chain stock expensive on trailing numbers. It trades at a price-to-earnings ratio of about 68.6 and roughly 9.9 times book value, against an industry PE near 62. Return on equity is around 15.2% and return on capital employed about 17.4%.
| Quarter | Promoters | FIIs | DIIs | Public |
|---|---|---|---|---|
| Jun 2025 | 33.01% | 11.54% | 12.20% | 43.19% |
| Sep 2025 | 33.01% | 11.41% | 12.97% | 42.56% |
| Dec 2025 | 33.01% | 10.54% | 13.99% | 42.41% |
| Mar 2026 | 33.01% | 10.15% | 14.76% | 42.01% |
| Jun 2026 | 33.00% | 9.46% | 16.89% | 40.55% |
The ownership trend in this multispecialty hospital chain stock is clear. Domestic institutions raised their stake from 12.20% to 16.89% in a year, while foreign investors trimmed theirs from 11.54% to 9.46%. Promoter holding has stayed flat at about 33%.
A rising domestic institutional base tends to support a multispecialty hospital chain stock during market dips. Falling foreign ownership, though, means one group of large investors has been selling into the rally.
What Is the Expansion Plan Behind This Multispecialty Hospital Chain Stock?
The company behind this multispecialty hospital chain stock plans to spend approximately Rs 4,850 crore over five years to add about 3,350 beds. Bed count stood at 3,737 at the end of June 2026, up from 3,042 in March 2025, and about 490 more beds are planned in FY27.
The pipeline includes a 400-bed hospital in South Delhi with a real estate partner, a 750-bed facility in Pitampura, a 650 to 750-bed hospital in Mumbai, an upgraded 650-bed project in Guwahati and a 400-bed unit in Varanasi. The Mumbai project alone is budgeted at about Rs 1,238 crore. This pipeline is the main reason the market still pays a premium for the multispecialty hospital chain stock.
If these hospitals follow the Lucknow and Patna playbook, the multispecialty hospital chain stock could have a long growth runway. The catch is that each new hospital needs two to four years to reach mature margins, so profits may lag revenue for some time.
Key Risks for This Multispecialty Hospital Chain Stock
Stretched valuation. This multispecialty hospital chain stock is priced for perfection. At about 68 times earnings, the Medanta share price already assumes several years of strong growth. Any slip in execution could lead to a sharp de-rating.
Profit lag from expansion. Borrowings rose to approximately Rs 1,190 crore at the end of FY26, and depreciation and interest costs will grow as new hospitals open. Flat profit in Q1 FY27 despite 26% revenue growth shows how quickly this can bite.
Execution and ramp-up risk. For a multispecialty hospital chain stock, expansion is the main risk. Five large projects across new cities, including a first entry into Mumbai, raise the risk of delays, cost overruns and slower occupancy.
Pricing and regulation. Any multispecialty hospital chain stock faces pricing risk. Hospital pricing faces scrutiny from regulators and insurers, and caps on procedure rates or tighter insurance terms could squeeze average revenue per bed.
Weak recent momentum. The one-month return of 1.38% ranks 80th of 101, which suggests the rally has paused. The multispecialty hospital chain stock could consolidate for a while after a near 50% six-month gain.
Download the Univest iOS App or Univest Android App to track the Medanta share price live
Medanta Share: Analyst View
Analyst sentiment on this multispecialty hospital chain stock is positive but no longer calls for large upside. Around 18 analysts track the Medanta share, and the consensus rating is buy, but the average target sits only a little above the current Medanta share price.
Medanta Share Price Target
The average Medanta share price target is approximately Rs 1,584, implying about 8% to 9% upside from around Rs 1,460. Individual estimates range from Rs 1,410 to Rs 1,799, so the most bullish Medanta share price target points to roughly 23% upside, while the lowest sits below the current price.
For context, a foreign brokerage set a Rs 1,500 target in May 2026, which the Medanta share price has already come close to crossing. Investors can also track the 52-week high of about Rs 1,544 as a near-term level and the Rs 1,300 zone, where a large fund bought shares in June, as a support area. Targets are estimates and can change after each quarterly result. Targets are estimates, and the multispecialty hospital chain stock could trade outside this range.
Conclusion
This multispecialty hospital chain stock has delivered a 264% gain since listing because the business grew into its valuation: revenue doubled, profit nearly tripled, and newer hospitals in Lucknow, Patna and Noida kept adding scale. The recent six-month rally was fuelled by strong Q4 FY26 numbers, a faster Noida ramp-up and steady domestic fund buying.
The next leg depends on execution. The Medanta share price trades at a rich multiple, profit growth has stalled in the latest quarter, and a Rs 4,850 crore expansion will pressure earnings before it lifts them. Long-term investors may prefer to watch Noida’s breakeven and occupancy at new hospitals before adding, rather than chasing the multispecialty hospital chain stock near its highs.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which multispecialty hospital chain stock rose 264% since listing?
Ans. Global Health Ltd, which runs Medanta hospitals (NSE: MEDANTA), is the multispecialty hospital chain stock that returned approximately 264.16% since its November 2022 listing, as of 10 September 2026. It ranked 29th out of 101 NSE stocks on the five-year return screen.
Why did the Medanta share price rise so much?
Ans. Revenue roughly doubled and net profit nearly tripled between FY22 and FY26 as hospitals in Lucknow and Patna matured. More recently, strong Q4 FY26 results, a faster Noida ramp-up and domestic fund buying pushed the stock up about 49.6% in six months.
What were Medanta Q1 FY27 results?
Ans. Revenue from operations rose about 26.5% year on year to Rs 1,304 crore in Q1 FY27, but net profit slipped slightly to around Rs 157 crore from Rs 159 crore. Higher depreciation and finance costs from new hospitals absorbed the operating gains.
What is the Medanta share price target?
Ans. The average analyst Medanta share price target is approximately Rs 1,584, with estimates ranging from Rs 1,410 to Rs 1,799. That implies modest upside of about 8% to 9% from around Rs 1,460, and targets can change after each result.
What is the 52-week high and low of Medanta?
Ans. The multispecialty hospital chain stock has a 52-week high of about Rs 1,544 and a 52-week low of around Rs 955. At approximately Rs 1,460 on 10 September 2026, it trades roughly 5% below its peak.
Is Medanta overvalued after the rally?
Ans. The stock trades at about 68.6 times trailing earnings and roughly 9.9 times book value, above the industry PE of about 62. Much of the expected growth is already priced in, so any delay in new hospitals could weigh on returns.
What was the Medanta IPO price and listing price?
Ans. The IPO was priced at Rs 336 per share and the stock opened at Rs 401 on NSE on 16 November 2022. There has been no split or bonus since, so the 264% gain from the listing price is genuine price appreciation.
Should I buy a multispecialty hospital chain stock after a 264% rise?
Ans. After a large rally, valuation risk is higher, so staggered buying and tracking occupancy and profit at new hospitals is sensible. Please consult a SEBI-registered advisor before making any investment decision.
